Sera Prognostics, Inc. (SERA)

$1.69

+0.04 (+2.42%)
Rating:
Recommendation:
-
Symbol SERA
Price $1.69
Beta 0.000
Volume Avg. 0.06M
Market Cap 52.394M
Shares () -
52 Week Range 1.15-11.41
1y Target Est -
DCF Unlevered SERA DCF ->
DCF Levered SERA LDCF ->
ROE -34.59% Strong Sell
ROA -36.84% Strong Sell
Operating Margin -
Debt / Equity 6.97% Neutral
P/E -
P/B 0.45 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SERA news


Healthcare
Diagnostics & Research
NASDAQ Global Market

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.